Suven Life Sciences share price today

Suven Life Sciences Ltd's share price was ₹276.10 at the close on 4 November 2026. It has been rising for 25 weeks. That is 2.2% above its average price over the last 200 trading days. In the last 52 weeks it traded between ₹130 and ₹378, and at that close it sat 59% of the way up from that low.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Suven Life Sciences Ltd is in stage 2. The phase helps read everything below.

Over the past 13 weeks it has done worse than the NIFTY 500, and it has been behind for 6 weeks running.

Over the last 11 years the share price moved +2,057% while the NIFTY 500 moved +251%, so it is ahead of the index over that whole period. It was last ahead over 13 weeks in the week of 28 September 2026. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

Three changes stood out: operating margin down 997 points on a year earlier, foreign funds (FIIs) cut their stake for 5 quarters in a row and indian funds and insurers (DIIs) cut their stake for 3 quarters in a row.

1. Operating margin down 997 points on a year earlier

   -3711% in the June 2026 quarter, from -2714%.

2. Foreign funds (FIIs) cut their stake for 5 quarters in a row

   From 1.2% to 0.5% of the company by the September 2026 quarter.

3. Indian funds and insurers (DIIs) cut their stake for 3 quarters in a row

   From 4.6% to 2.2% of the company by the September 2026 quarter.

For April to June 2026 (the quarter ended 30 June 2026), Suven Life Sciences reported revenue of ₹4.00 crore, up 100.0% from ₹2.00 crore a year earlier, and a loss of ₹128 crore.

Suven Life Sciences results: April to June 2026 against a year earlier

The next results, for July to September 2026, are due by 14 November 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter).

From the company's reported quarterly results (quarter ended 30 June 2026). Revenue and profit in ₹ crore.

Suven Life Sciences closed at ₹276.10 on 4 November 2026, up 45.6% from ₹189.68 a year earlier (7 November 2025) and up 188.6% over five years. Its highest weekly close since March 2016 was ₹378.00 on 4 September 2026.

Suven Life Sciences share price: then and now

Weekly closing prices. Each change is the move from that price to the 4 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes.

563 weekly closes from 11 March 2016 to 4 November 2026.

4 Nov 2026: Suven Life Sciences closed at ₹276.10, up 6.7% on the week and down 10.4% on the month. Results for April to June 2026: Revenue up 100.0% on a year earlier.

Suven Life Sciences has paid no dividend on the NSE since 1 April 2021, the start of the period we checked.

Not in its latest year. Suven Life Sciences Ltd paid out 0% of its profit as dividends in FY26. It did pay a dividend in 5 of its last 13 reported years, so there is a history but no current dividend.

From the NSE corporate-actions record, read 5 November 2026.

Suven Life Sciences is on one of our India lists: Pharma stocks.

Suven Life Sciences Ltd posted a net loss of ₹128 Cr in the Jun 2026 quarter. That quarter includes a one-off gain bigger than its revenue, so the comparison with last year does not reflect normal business. The full FY26 year was a loss of ₹276 Cr. That loss is 3,200.0% of the quarter's revenue.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

The same quarter a year earlier lost ₹52.0 Cr. 12 of the last 12 reported quarters were loss-making.

Read this profit with care: at −₹128 Cr it is bigger than the quarter's whole revenue of ₹4.0 Cr. No business earns more than it takes in from sales, so this is a one-off item (for example a debt settlement, a tax write-back or an asset sale), not money the business earned. The underlying business is running at a −3,711.0% operating margin. The jump on last year, and any P/E built on this profit, come from the one-off, not from a real turn in earnings.

Suven Life Sciences Ltd reported ₹4.0 Cr of revenue in the Jun 2026 quarter, +100.0% on the same quarter a year earlier. That is the 3rd quarter in a row with growth on the year before. Over 10 years it has grown −34.7% a year on average. The last full year, FY26, came in at ₹7.0 Cr.

Revenue is everything the company billed its customers in the period.

The last four reported quarters add to ₹10.0 Cr.

FY26 revenue was ₹7.0 Cr, +0.0% on the year before.

Recent pace: the last four quarters grew +45.8% on average, against −34.7% a year over the longer run, so this year is growing faster than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew +25.0%, against +11.8% a year over the last 8 quarters (accelerating).

Suven Life Sciences Ltd's sales have fallen to very little: FY26 revenue was ₹7.0 Cr, against ₹625 Cr in FY18. On sales that small an operating margin is not a useful reading, so this section is left out until sales recover.

Over the last 3 years, 87% of Suven Life Sciences Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 its operations used ₹300 Cr of cash, against −₹276 Cr of profit.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

After ₹23.0 Cr of spending on assets, free cash was −₹323 Cr: it spent more than its operations brought in.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why: the cash figure is clear, but the day counts behind it are not in our data, so we show it without guessing the reason.

What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building.

Suven Life Sciences Ltd's customer, stock and supplier day counts are not a useful reading on sales this small (₹7.0 Cr in FY26), so no cash-cycle chart is drawn and this section looks at its spending on assets instead. It spent ₹58.0 Cr on assets over the last 3 years.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

Averaged over those years that is 276.2% of FY26 revenue a year.

Spending on assets: ₹58.0 Cr over the last 3 years, against ₹18.0 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹4.0 Cr (FY26): assets paid for that are not earning yet.

In short: most of the cash goes on covering the loss, not on new assets; spending on assets is small next to it.

Suven Life Sciences Ltd's P/E is 2.6×, near the low end of its own history: it has been lower only 16% of the time. Its usual P/E (the middle reading) is 3.2×, over 3 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.

Where the price move came from: over 3 years the price moved +52.4% a year; about +23.4% a year came from earnings growth and about +29.0 percentage points from the multiple (the market paying more). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple.

In short: the multiple is low against its own past, so the earnings trend underneath matters more than the multiple.

Suven Life Sciences Ltd's business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 12 quarters of 2 measures, with some gaps.

Every business is somewhere on a path of getting better or worse, and this section names where. The last 12 quarters of growth in revenue, profit and earnings per share, plus the return the business earns on its capital, are read as lines. Getting worse: the lines are falling. Turning around: a low point has just formed and the last few quarters are rising from it. Getting better: the rise from the low has lasted. Growing steadily: steady growth with healthy returns. Slowing from a peak: still high, but slowing. When the lines disagree the result is mixed; too little history means no reading. CAGR (compound annual growth rate) is the steady yearly rate that would turn the starting value into the latest one. It is the fairest way to compare growth over different periods. If the 1-year figure is much bigger than the 10-year one, recent growth is running faster than the long-run trend. A dash means there is no figure for that period, or the starting year was a loss, where a growth rate means nothing.

Why it matters: with too little history, we say so rather than guess a direction.

The latest quarter’s profit includes a one-off item bigger than the normal business, so the profit line is shown but does not count in this reading.

The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone.

There are fewer than eight usable quarters, so this page does not guess a direction from so little history.

Compound annual growth rate (%)

Compound annual growth rate over each period, %. Revenue, profit and EPS come from yearly figures; the share price row is price growth over the same periods. A dash means no figure for that period, or the starting year was a loss.

Suven Life Sciences Ltd earned a ROCE of −80% in FY26. That is up from a low of −118% in FY22. Its return on capital used (ROIC) is left out: on sales this small it reads −440%, a number that says nothing useful about the business.

Return on capital employed (ROCE) is the profit the whole business earns on all the money in it, from shareholders and lenders together. It is the best single test of whether growth adds value or just size.